NeoGenomics Inc (NASDAQ:NEO) reported a 10% year-over-year revenue growth in Q3, with clinical business revenues growing by 14%, marking a record quarter in total test volume and revenues.

NeoGenomics Stock Performance Shares of NASDAQ NEO opened at $14.14 on Tuesday. The company has a current ratio of 2.01, a quick ratio of 1.93 and a debt-to-equity ratio of 0.37. NeoGenomics, Inc ...

As a significant indicator of economic activity and compliance, GST revenue collections not only reflect the health of the economy but also the effectiveness of the tax system in enhancing the ...

According to generally accepted accounting principles (GAAP), the following two criteria must be satisfied before the company can record revenue on its books: A critical event must trigger the ...

In the third quarter (Q3) alone, SAIC Motor logged revenue of 145.796 billion yuan, down by 25.91% compared to the previous year, while net profit attributable to shareholders reached 279.69 million y ...

Berkshire Hathaway Inc. Cl A-1.95% $974.27B Berkshire Hathaway Inc. Cl B-2.18% $974.27B ...

As YouTube grew, it added more features to serve content creators, such as ratings, comments, embed functionality, live-streaming and revenue sharing. Many celebrities have gotten their start through ...

ChatGPT has taken the world by storm, setting a record for the fastest user growth when it launched reaching 100 million users in two months. The implications of this tool are far-reaching, with ...

Nearly 160,000 drivers in the UK are at risk of becoming a victim of mileage ...